Leonardo Biosystems

Arrowhead Research this week reported its fiscal fourth-quarter financial results, posting a higher net loss amid increased operating expenses.
The company also said that efforts to integrate its subsidiaries into a single company are underway.

Leonardo Biosystems said this week that it has received the second half of a $2.5 million grant from the Texas Emerging Technology Fund to help develop its multi-stage drug-delivery technology.
The first half of the grant was received in April 2010.

People in the News

Premium

Arrowhead Research has appointed Bruce Given as its COO.

People in the News

Premium

Mauro Ferrari

Leonardo, which had been expecting the funding, intends to use the money to ramp up its operations with the goal of securing industry partnerships around its so-called multi-stage delivery approach.

While the company may at some point down the road dip its toes into the drug-development waters, "initially, I don't see us having any in-house discovery efforts," Leonardo CEO Bruce Given said.

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.